No Evidence of QTc Interval Prolongation With Baxdrostat Treatment: Concentration–QTc Modeling Assessment
ABSTRACT Baxdrostat is a novel, highly potent, selective, competitive inhibitor of human aldosterone synthase currently under development for the treatment of uncontrolled and resistant hypertension and chronic kidney disease. We assessed the risk of QTc‐interval prolongation with baxdrostat using c...
Salvato in:
| Autori principali: | , , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Wiley
2025-10-01
|
| Serie: | Pharmacology Research & Perspectives |
| Soggetti: | |
| Accesso online: | https://doi.org/10.1002/prp2.70181 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|